KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Neogenomics (NEO) over the last 3 years, with Jun 2012 value amounting to $28.0 million.

  • Neogenomics' Cash & Equivalents fell 54.66% to $164.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.1 million, marking a year-over-year decrease of 54.66%. This contributed to the annual value of $367.0 million for FY2024, which is 7.16% up from last year.
  • As of Q3 2025, Neogenomics' Cash & Equivalents stood at $164.1 million, which was up 6.07% from $154.7 million recorded in Q2 2025.
  • Neogenomics' Cash & Equivalents' 5-year high stood at $612.0 million during Q1 2021, with a 5-year trough of $154.7 million in Q2 2025.
  • Over the past 3 years, Neogenomics' median Cash & Equivalents value was $331.9 million (recorded in 2024), while the average stood at $299.5 million.
  • Data for Neogenomics' Revenue - Interest and Investment Income shows a peak YoY soared of 68.09% (in 2012) over the last 5 years.
  • Neogenomics' Revenue - Interest and Investment Income (Quarterly) stood at $12.9 million in 2009, then climbed by 5.45% to $13.7 million in 2010, then spiked by 46.14% to $19.9 million in 2011, then spiked by 68.09% to $28.0 million in 2012.
  • Its Cash & Equivalents stands at $164.1 million for Q3 2025, versus $154.7 million for Q2 2025 and $346.2 million for Q1 2025.